TY - JOUR
T1 - We'll always have Paris The Paris System for Reporting Urinary Cytology 2022
AU - Wojcik, Eva M.
AU - Kurtycz, Daniel F.I.
AU - Rosenthal, Dorothy L.
N1 - Publisher Copyright:
© 2022 American Society of Cytopathology
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Following the amazing acceptance of The Paris System for Reporting Urinary Cytology (TPS), the second edition (TPS 2.0) was inevitable. Based on new studies since the publication of the first edition, diagnostic criteria are refined, and pitfalls discussed. In addition to reinforcing the mandate that the focus of diagnostic urinary cytology is the detection of high-grade urothelial carcinoma, other issues are addressed. Low-grade lesions are included in the category of negative for high-grade urothelial cancer. The rationale for that decision is strongly supported by evidence from the authors’ experiences as well as the recent literature. A new chapter on urine cytology of the upper tract, a rarely addressed topic, explores the challenges involved. Furthermore, the issue of cellular degeneration is discussed in the criteria of all diagnostic categories. Most importantly, data defining the risk of high-grade malignancy (ROHM) for each diagnostic category informs clinical management. The 65 authors are recognized authorities from 33 countries, attesting to the global impact of TPS 2.0.
AB - Following the amazing acceptance of The Paris System for Reporting Urinary Cytology (TPS), the second edition (TPS 2.0) was inevitable. Based on new studies since the publication of the first edition, diagnostic criteria are refined, and pitfalls discussed. In addition to reinforcing the mandate that the focus of diagnostic urinary cytology is the detection of high-grade urothelial carcinoma, other issues are addressed. Low-grade lesions are included in the category of negative for high-grade urothelial cancer. The rationale for that decision is strongly supported by evidence from the authors’ experiences as well as the recent literature. A new chapter on urine cytology of the upper tract, a rarely addressed topic, explores the challenges involved. Furthermore, the issue of cellular degeneration is discussed in the criteria of all diagnostic categories. Most importantly, data defining the risk of high-grade malignancy (ROHM) for each diagnostic category informs clinical management. The 65 authors are recognized authorities from 33 countries, attesting to the global impact of TPS 2.0.
KW - Diagnostic system
KW - Malignancies of the urinary tract
KW - Urinary cytology
KW - Urothelial carcinoma
KW - Urothelial neoplasia
UR - http://www.scopus.com/inward/record.url?scp=85123729228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123729228&partnerID=8YFLogxK
U2 - 10.1016/j.jasc.2021.12.003
DO - 10.1016/j.jasc.2021.12.003
M3 - Article
C2 - 35094954
AN - SCOPUS:85123729228
SN - 2213-2945
VL - 11
SP - 62
EP - 66
JO - Journal of the American Society of Cytopathology
JF - Journal of the American Society of Cytopathology
IS - 2
ER -